Synthetic Blood International Announces Television News Coverage
COSTA MESA, Calif., Dec 2, 2003 (BUSINESS WIRE) -- Synthetic Blood
International Inc. (OTCBB: SYBD), announced today that the company was featured
on a local news program broadcast last week by a local cable television station
serving Southern California.
The focus of the story was Oxycyte(TM), the company's perfluorocarbon based
blood substitute and therapeutic oxygen carrier, which is in the final stages of
the Phase I human safety study.
"This is timely coverage because we started the final part of the Phase I study
today. This involves dosing at the third and highest level in the last group of
study participants. The results thus far have been good and consistent with our
expectations," says Robert Nicora, SYBD president. "The independent study site
is on track to complete the study by the end of the year."
Last month, the Los Angeles Times Costa Mesa Daily Pilot reported on the
progress of clinical testing for Oxycyte. The company plans to post the cable
news Oxycyte report on its Web site, www.sybd.com, in the near future
While the company has sufficient capital to complete the Phase I study as well
as at least two Phase II studies, the company cautions that there can be no
guarantees regarding its ability to raise additional capital, or to predict the
outcome of clinical trials.
In addition to Oxycyte, SYBD is also developing Fluorovent(TM), a liquid
ventilation product that may be useful in treating respiratory disorders in
adults and children. The company is also developing an implantable glucose
biosensor for the continuous monitoring of blood glucose levels in diabetics.
SOURCE: Synthetic Blood International Inc.
CONTACT:
Synthetic Blood International Inc., Costa Mesa
Joan Mahan, 714-427-6363 or 800-809-6054 |
